| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Ocugen, Inc. | CFO/CBO | Common Stock | 165,934 | $108,355 | $0.6530 | 06 Mar 2023 | Direct |
| Monopar Therapeutics | Chief Financial Officer | Common Stock | 1,500 | $104,925 | $69.95 | 26 Dec 2025 | Direct |
| 180 Life Sciences Corp. | COO / Chief Business Officer | Common Stock | 20,500 | $3,854 | $0.1880 | 16 Dec 2021 | Direct |
| 180 Life Sciences Corp. | COO / Chief Business Officer | Stock Option (Right to Buy) | 275,000 | 08 Dec 2021 | Direct | ||
| Monopar Therapeutics | Chief Financial Officer | Restricted Stock Units | 9,826 | 02 Dec 2025 | Direct | ||
| Monopar Therapeutics | Chief Financial Officer | Stock Options | 7,135 | 02 Dec 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| MNPR | Monopar Therapeutics | 26 Dec 2025 | 1 | +$104,925 | 4 | Chief Financial Officer | 29 Dec 2025, 12:15 |
| MNPR | Monopar Therapeutics | 02 Dec 2025 | 2 | $0 | 4 | Chief Financial Officer | 08 Dec 2025, 16:47 |
| MNPR | Monopar Therapeutics | 03 Mar 2025 | 1 | $0 | 4 | Chief Financial Officer | 05 Mar 2025, 16:06 |
| MNPR | Monopar Therapeutics | 03 Mar 2025 | 0 | $0 | 3 | Chief Financial Officer | 05 Mar 2025, 16:05 |
| OCGN | Ocugen, Inc. | 06 Mar 2023 | 0 | $0 | 3 | CFO/CBO | 10 Mar 2023, 18:26 |
| ATNF | 180 Life Sciences Corp. | 16 Dec 2021 | 1 | +$31,840 | 4 | COO / Chief Business Officer | 16 Dec 2021, 16:00 |
| ATNF | 180 Life Sciences Corp. | 10 Dec 2021 | 1 | +$17,550 | 4 | COO / Chief Business Officer | 10 Dec 2021, 17:04 |
| ATNF | 180 Life Sciences Corp. | 08 Dec 2021 | 1 | $0 | 4 | COO / Chief Business Officer | 10 Dec 2021, 07:20 |
| ATNF | 180 Life Sciences Corp. | 29 Oct 2021 | 0 | $0 | 3 | COO / Chief Business Officer | 04 Nov 2021, 18:47 |